Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1980-1-19
pubmed:abstractText
The effects of intravenous tranexamic acid were compared with placebo in 64 patients with subarachnoid hemorrhage. A double-blind procedure was used. One gram of tranexamic acid was given intravenously every 4 hours up to the time of operation on an intracranial arterial aneurysm or for up to 21 days after the first bleeding if operative treatment was not feasible. There were no differences in re-bleeds, morbidity or mortality between the tranexamic and placebo-treated groups. No thromboembolic complications were noted in either group. Our results do not support the use of tranexamic acid in subarachnoid hemorrhage in daily doses of 6 g.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0039-2499
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
519-22
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:505491-Adolescent, pubmed-meshheading:505491-Adult, pubmed-meshheading:505491-Cerebral Ventricles, pubmed-meshheading:505491-Child, pubmed-meshheading:505491-Cyclohexanecarboxylic Acids, pubmed-meshheading:505491-Dilatation, Pathologic, pubmed-meshheading:505491-Double-Blind Method, pubmed-meshheading:505491-Drug Evaluation, pubmed-meshheading:505491-Female, pubmed-meshheading:505491-Humans, pubmed-meshheading:505491-Injections, Intravenous, pubmed-meshheading:505491-Intracranial Aneurysm, pubmed-meshheading:505491-Ischemic Attack, Transient, pubmed-meshheading:505491-Male, pubmed-meshheading:505491-Middle Aged, pubmed-meshheading:505491-Placebos, pubmed-meshheading:505491-Preoperative Care, pubmed-meshheading:505491-Subarachnoid Hemorrhage, pubmed-meshheading:505491-Tranexamic Acid
pubmed:articleTitle
Tranexamic acid in subarachnoid hemorrhage. A double-blind study.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, Non-P.H.S., Controlled Clinical Trial